JP2021511013A - シングルドメイン抗体−シトシンデアミナーゼ融合タンパク質 - Google Patents

シングルドメイン抗体−シトシンデアミナーゼ融合タンパク質 Download PDF

Info

Publication number
JP2021511013A
JP2021511013A JP2020532877A JP2020532877A JP2021511013A JP 2021511013 A JP2021511013 A JP 2021511013A JP 2020532877 A JP2020532877 A JP 2020532877A JP 2020532877 A JP2020532877 A JP 2020532877A JP 2021511013 A JP2021511013 A JP 2021511013A
Authority
JP
Japan
Prior art keywords
seq
fusion protein
functional variant
sdab
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020532877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511013A5 (OSRAM
Inventor
ペイ−ジウン チェン
ペイ−ジウン チェン
シュー−フア リー
シュー−フア リー
Original Assignee
シャンハイ ルーモサ セラピューティクス カンパニー リミテッド
シャンハイ ルーモサ セラピューティクス カンパニー リミテッド
ルモサ セラピューティクス カンパニー， リミテッド
ルモサ セラピューティクス カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ ルーモサ セラピューティクス カンパニー リミテッド, シャンハイ ルーモサ セラピューティクス カンパニー リミテッド, ルモサ セラピューティクス カンパニー， リミテッド, ルモサ セラピューティクス カンパニー， リミテッド filed Critical シャンハイ ルーモサ セラピューティクス カンパニー リミテッド
Publication of JP2021511013A publication Critical patent/JP2021511013A/ja
Publication of JP2021511013A5 publication Critical patent/JP2021511013A5/ja
Priority to JP2023111309A priority Critical patent/JP2023126935A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020532877A 2018-01-04 2019-01-04 シングルドメイン抗体−シトシンデアミナーゼ融合タンパク質 Pending JP2021511013A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023111309A JP2023126935A (ja) 2018-01-04 2023-07-06 シングルドメイン抗体－シトシンデアミナーゼ融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862613653P 2018-01-04 2018-01-04
US62/613,653 2018-01-04
PCT/IB2019/000013 WO2019135159A2 (en) 2018-01-04 2019-01-04 Single-domain antibody-cytosine deaminase fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023111309A Division JP2023126935A (ja) 2018-01-04 2023-07-06 シングルドメイン抗体－シトシンデアミナーゼ融合タンパク質

Publications (2)

Publication Number Publication Date
JP2021511013A true JP2021511013A (ja) 2021-05-06
JP2021511013A5 JP2021511013A5 (OSRAM) 2021-12-23

Family

ID=67058005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532877A Pending JP2021511013A (ja) 2018-01-04 2019-01-04 シングルドメイン抗体−シトシンデアミナーゼ融合タンパク質
JP2023111309A Withdrawn JP2023126935A (ja) 2018-01-04 2023-07-06 シングルドメイン抗体－シトシンデアミナーゼ融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023111309A Withdrawn JP2023126935A (ja) 2018-01-04 2023-07-06 シングルドメイン抗体－シトシンデアミナーゼ融合タンパク質

Country Status (14)

Country Link
US (2) US20190202931A1 (OSRAM)
EP (1) EP3735420A4 (OSRAM)
JP (2) JP2021511013A (OSRAM)
KR (1) KR20200106032A (OSRAM)
CN (1) CN112272673A (OSRAM)
AU (1) AU2019205128A1 (OSRAM)
BR (1) BR112020013244A2 (OSRAM)
CA (1) CA3087135A1 (OSRAM)
IL (1) IL275691A (OSRAM)
MX (1) MX2020006822A (OSRAM)
RU (1) RU2020116541A (OSRAM)
TW (1) TW201932487A (OSRAM)
WO (1) WO2019135159A2 (OSRAM)
ZA (1) ZA202003893B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527496B (zh) * 2020-04-16 2022-03-04 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
EP4135733A4 (en) * 2020-04-17 2024-06-26 University of Cincinnati MODIFIED PROBIOTICS FOR TREATMENT AND IMMUNITY AGAINST VIRUSES
CA3205007A1 (en) * 2020-12-17 2022-06-23 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
WO2022152862A1 (en) * 2021-01-14 2022-07-21 Institut Curie Her2 single domain antibodies variants and cars thereof
CN118215685A (zh) * 2021-12-27 2024-06-18 山东先声生物制药有限公司 抗gucy2c抗体及其应用
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
CN119604536A (zh) * 2022-05-23 2025-03-11 塞雷乌斯股份有限公司 Her2结合剂及其用途
CN116655806B (zh) * 2023-05-31 2024-01-05 四川大学华西医院 包含shp2 c-sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02223532A (ja) * 1987-08-04 1990-09-05 Bristol Myers Co 腫瘍細胞に細胞障害性物質を供給するためのプロドラッグと組合せた抗体−酵素結合体
JPH06319554A (ja) * 1993-05-04 1994-11-22 Behringwerke Ag 修飾炭水化物補完体を有する二機能性糖タンパク質と腫瘍選択療法におけるそれらの用途
JP2011144191A (ja) * 2003-07-31 2011-07-28 Immunomedics Inc 抗ｃｄ１９抗体
US20130203964A1 (en) * 2010-06-21 2013-08-08 Diatheva S.R.L. Antibody derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
ES2528922T3 (es) * 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
WO2009068631A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2757382A1 (en) * 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02223532A (ja) * 1987-08-04 1990-09-05 Bristol Myers Co 腫瘍細胞に細胞障害性物質を供給するためのプロドラッグと組合せた抗体−酵素結合体
JPH06319554A (ja) * 1993-05-04 1994-11-22 Behringwerke Ag 修飾炭水化物補完体を有する二機能性糖タンパク質と腫瘍選択療法におけるそれらの用途
JP2011144191A (ja) * 2003-07-31 2011-07-28 Immunomedics Inc 抗ｃｄ１９抗体
US20130203964A1 (en) * 2010-06-21 2013-08-08 Diatheva S.R.L. Antibody derivatives

Also Published As

Publication number Publication date
BR112020013244A2 (pt) 2020-12-01
KR20200106032A (ko) 2020-09-10
CA3087135A1 (en) 2019-07-11
MX2020006822A (es) 2020-09-03
WO2019135159A2 (en) 2019-07-11
EP3735420A4 (en) 2021-10-06
EP3735420A2 (en) 2020-11-11
TW201932487A (zh) 2019-08-16
WO2019135159A3 (en) 2020-02-13
CN112272673A (zh) 2021-01-26
JP2023126935A (ja) 2023-09-12
RU2020116541A3 (OSRAM) 2022-02-28
ZA202003893B (en) 2022-11-30
US20220056149A1 (en) 2022-02-24
RU2020116541A (ru) 2022-02-04
US20190202931A1 (en) 2019-07-04
AU2019205128A1 (en) 2020-07-16
IL275691A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
JP2023126935A (ja) シングルドメイン抗体－シトシンデアミナーゼ融合タンパク質
TWI847992B (zh) 抗體-藥物結合物之有效的製造方法
US10543284B2 (en) Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof
US12527979B2 (en) Treatment of HER3-mutated cancer by administration of anti-HER3 antibody-drug conjugate
CN112601554A (zh) 肿瘤微环境活化的药物-结合剂缀合物和与其相关的用途
US20180230219A1 (en) Vegfr-2 car immune cells to treat cancers
EP3194450A1 (en) Multivalent fragments of antibody 3e10 and methods of use thereof
TW202547842A (zh) 抗c-Met抗體藥物結合物
US20200054764A1 (en) Medical use of anti-c met antibody-cytotoxic drug conjugate
CN116134138B (zh) 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途
TWI862982B (zh) 抗體–藥物結合物之用途
KR20230103244A (ko) 항-HER2 scFv 및 CP2c 표적 펩티드를 포함하는 이중표적 단백질 및 이의 용도
JP2020506675A (ja) Ｖｅｇｆｒ−２抗体
HK40036942A (en) Single-domain antibody-cytosine deaminase fusion proteins
CA3113207C (en) Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
CN115124621A (zh) 靶向pd-l1的纳米抗体及其制备方法和应用
EP3580242A1 (en) Anti-vegfr-2 urease conjugates
TW202508639A (zh) 包含使用活性碳材料之純化步驟的抗體-藥物結合物之製造方法
US20250000991A1 (en) Nectin-4 antibodies and antibody-drug conjugates
HK40046216A (en) Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307